1: evaluation of clinical economics: medical content i; presentation of questions ii; basic concepts and methods of economics evaluation; examples of economics evaluation iv; quality standards i of clinical economics evaluation studies; content i; presentation of questions 33; complete and incomplete economic evaluation; evaluation of cost and effect at the same time as results + cost-effectiveness-cost + 2 or more programmes to describe cost-effectiveness - description of impact as complete economics evaluation of effectiveness/impact evaluation cost analysis: cost minimization analysis cost-effect analysis cost-benefit analysis53, complete and incomplete economic evaluation comparison of cost and effect evaluation with impact +44, results of commonly used economic analysis type, results analysis method cost minimization analysis (cost minimum analysis, cma) indirect cost assumptions or validated programme results
2. Analysis of cost-effectiveness analysis of cost-benefits of cost-effectiveness of cost-benefit ratios for qalys per year of failure to adjust lifetimes (dalys), not necessarily the same as for the qalys) and cost-benefit analysis of cost-effectiveness of cost-benefit ratios for dalys (cost benefit economics, cba) for the harmonized results of the previous programmes: intermediate indicators, cost-effectiveness analysis of cost-effectiveness analysis of cost-effect ratios for end indicators (cost-effect ratios, cba) and monetary values of results not necessarily the same for the individual programmes: human capital approach, method of yield rate of return of the rate of the rate of return of the rate of the ratio of the net present value of the willing payment method, method of common economic analysis yes
3. An example of this is the 58-year-old female, who is 1. 56 m tall and weighs 65 k. Bmi = 26. 7 v. “drinking, drinking, urinating, indigence for six months, aggravated by january”. No abnormally empty abdominal sugar 7. 8 mmol/l was found during the medical examination, and the oral sugar tolerance test showed an empty abdominal sugar 7. 5 mmol/l, followed by a two-hour blood sugar 12. 3 mmol/l. Blood pressure, blood resin normal, blood urine routines, liver kidneys, electrocardiograms, liver cystic double kidneys with an abnormal diagnosis of type 2 diabetes. 73 the clinical economics evaluation exemplifies the 58-year-old female treatment course “china diabetes control guide” 20198 “china diabetes control guide” 20197 a-decatra-dium 2019, the international diabetes alliance (idf) published a new consensus on type 2 diabetes treatment, published in conjunction with the global guide to type 2 diabetes esd/ada
4. Further advance the use of the digalactic diaphragm and recommend that joint treatment programmes for newly diagnosed diabetic patients should include a combination of two-decadeca and nine-deca and two-deca and eight-deca and two-deca of 2019, as long as the patient is able to withstand the combination of lifestyle interventions: the obvious sugar effect cochrane review, the uk forward diabetes study (ukds) to reduce cardiovascular complications cochrane review, the ukpds study, presto research to control weight ukpds, cochrane review to improve the sensitivity of insulin, the dpp study, cochrane review, the common adverse effect of safety is the rareness of ulcated acid reaction in the gastrointestinal tract (120% of general bodyweight), fpg: 6. 0 - fpg:
5, 15 mmol/lwithout symptoms of hyperglycaemiano any long-term community study with type blood control target
6-mol/l without symptomies of hyperglycaemia when following a diet not have any long-term communication i: intended blood glucose coNtrol with metforminaimed at obtaining near-normal fpg (i. E., 6. 0 mmmol/l) c:usual care: recommended at clinical clinics every three months (upps 34)
7. O: cost-efficties25 research purpose/research issuesDoes the economic analysis approach confirm the effectiveness of the intervention? Whether the effects are confirmed through random control trials? Or through systematic evaluation of clinical trials or mEta analysis confirms? Or uses observational data or assumptions? Is there a potential bias in the outcome? 273) has the effect of the intervention been confirmed? Is the 26-effect data source identified through random control tests:
8 ess data: a series of uk forward diabetes studies published (e. G. Ukpds 34 and ukpds 62) on the probabilities of transformation between health states (transaction policy) and risk ratios for complications (risk radio) are mainly based on expert opinions. Is there a possible partial bias that might be appropriate in china? 28 effect data source: the effects dat 27qalys' utility values for different health states are mainly derived from literature (e. G. Ukpds 62 study) from expert estimates for “complicated f: kidney failure” and “serious complications”. 3% utility of discounting unreported specific literature search methods and inclusion
The possible differences in demographic characteristics and political, economic, cultural and other aspects between china (including research site beijing) and the united kingdom, which have led to the possibility that british data are not the most appropriate simulation of china's situation, and whether the utility values that give rise to 29qalys' different state of health are most appropriately identified and measured from the literature (e. G. Ukpds284)? Are all the key information on costs and outcomes included in the analysis in the programmes? Are appropriate measurement units used to measure costs and results? Are the values of costs and outcomes credible? Have the costs and results been corrected over time? Is the discount rate reasonable? 304) are costs and results properly identified and measured? 29 cost data collection: the costs: only the costs of managing direct medical costs of diabetes are considered (e. G. Counselling, education, doctor visits, blood sugar surveillance, biochemical indicator testing, urine routines, diabetes foot and eye)
The cost of a drug-cost transition (the cost of a transition from one state of health to another) for the treatment of a health condition (including a state of complications) does not take into account the cost of an adverse event, which the author mentions may be a small part of the total cost. Most of the cost data is derived from expert opinions, in part from a 3 per cent cost discount on publications. The health services-related costs considered in the study are more comprehensive, but the main cost data are derived from expert estimates and obtained only through face-to-face or telephone interviews with eight beijing experts, which may affect the reliability of expert estimates. 31 cost data collection: the costs: costs of direct health care
11, abetes 31 costas (rmb) of dlugs and incorporated cost in the two treatiesJust on weished market share, and a daily dose of 1500 mg or 2550 mg33chosts (rbb) of drags and ind32transion (event) host (rmb) of conflicts 34transion (event) cost (rmb33state) costs (rmb) of operations 35s
12, date (annual) costs o34 effect state effectsOn uskpds 62*36 effect state independence values bIs the economic analysis type appropriate? Information
13, l cost-use economic analysis model using the markov model for a one-year cycle analyses whether the cost-effectiveness assumption for 11 years and throughout the life cycle for type 2 diabetic diabetic diaphragm intensive treatment and diet-based routine treatments is appropriate, using beijing as the three-fold threshold of per capita GDP 385). The surveyal co37 reality evaluation summary uses the markov model to evaluate the incremental cost-effectiveness of two-acre amplification treatment compared with conventional information based on dietary control in the health service system. The study was based on the uk uk ukkpds 34 study and did not provide a detailed description of how its interventions were implemented, and the impact data were mainly from a series of published uk forwards
Sexual diabetes studies consider only direct medical costs and are more comprehensive; the reliability of the data may be affected by the fact that the main cost data come from expert estimates and the expert approach is limited. The economics evaluation used an appropriate cost-effectiveness analysis. The economic analysis is generally of better quality, but because impact data are mainly from the united kingdom, it may not be the best source of effect data due to differences between the study population and clinical practice in both countries; at the same time, cost data may come mainly from expert estimates and may result in bias in the evaluation of the 39-realistic summary using the markov model (what is the result of markov model38 evidence?) what is the incremental cost effect? Are the incremental cost effects of the sub-groups different? The extent to which uncertainty affects research findings? What is the result of the evidence
The incremental cost-effect ratio of cqalys (e) to conventional treatment 5. 66. 59 a-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-d-
16, %-10. 56-17. 10 other drug-cost intensive treatment group 1, 0004. 68. 033. 2 conventional treatment group 07. 63. 00016. 5 conventional management cost of diabetes mellitus 50013. 15. 00016. 1 dzQuestion 1. A properly and specifically defined question study examines the cost and results of the intervention project
17 questions. Are comparisons between different programmes involved? Are the analytical perspectives clearly presented? 2. Are there significant gaps in programmes to be compared, such as time, place, target, methodology, etc.? Are gaps to be considered? Are the methods used appropriate and effective and logical? Criteria for the quality of clinical economics evaluation studies 1. Questions raised 443. Have the effects of intervention projects been confirmed? Are the effects confirmed through randomly cross-checked clinical trials? The effects are confirmed through an overview of clinical trials? Are observations or assumptions used? Is there a potential bias in the outcome? Are all the key information on costs and results included in the programmes? 5. Are costs and results measured in appropriate metrics? 6. Are the values of costs and outcomes credible? 7. Have the costs and results been corrected at different times? Is the discount rate reasonable? 8.
18. Are there incremental analyses of programme costs and results? Has the effect of the intervention project been demonstrated? 459. Have uncertainties been taken into account in estimating costs and results? Are there data uncertainties? If so, is the range of values taken from key parameters reasonable? Are the results of the study sensitive to value-taking changes? 10. Are the findings and discussions given inclusive of all the concerns of the users of the study? Is the analysis based on an overall indicator or cost-effectiveness ratio? Are the results compared with similar studies? Are potential methodological differences taken into account in the comparison? Has the generality of the findings been discussed? Have other important factors influencing decision-making (e. G. Cost, distribution of results, ethical issues, etc.) been considered to discuss the implementation or application of research findings and constraints? 4746 references: uhu, editor-in-chief, health economics. University of jordan press. Shanghai, 2019 zhongqing, editor-in-chief, hudwei, health economics. China, statistical press. Beijing, 2019. 10 drummond mf, sculpher mj, torra
